Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance
- 31 October 2011
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (5) , 467-472
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Practical management of tyrosine kinase inhibitor-associated side effects in GISTCancer Treatment Reviews, 2011
- Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumorCancer Chemotherapy and Pharmacology, 2010
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialThe Lancet Oncology, 2010
- Imatinib mesylate for the treatment of gastrointestinal stromal tumorExpert Review of Anticancer Therapy, 2010
- Imatinib plasma levels: correlation with clinical benefit in GIST patientsBritish Journal of Cancer, 2010
- Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug ResistanceClinical Cancer Research, 2009
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000